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Spinal and bulbar muscular atrophy (SBMA) is a motor neuron disease caused by polyglutamine expansion
mutation in the androgen receptor (AR). We investigated whether the mutant protein alters mitochondrial
function. We found that constitutive and doxycycline-induced expression of the mutant AR in MN-1 and
PC12 cells, respectively, are associated with depolarization of the mitochondrial membrane. This was miti-
gated by cyclosporine A, which inhibits opening of the mitochondrial permeability transition pore. We also
found that the expression of the mutant protein in the presence of ligand results in an elevated level of reac-
tive oxygen species, which is blocked by the treatment with the antioxidants co-enzyme Q10 and idebenone.
The mutant protein in MN-1 cells also resulted in increased Bax, caspase 9 and caspase 3. We assessed the
effects of mutant AR on the transcription of mitochondrial proteins and found altered expression of the per-
oxisome proliferator-activated receptor g coactivator 1 and the mitochondrial speciﬁc antioxidant superoxide
dismutase-2 in affected tissues of SBMA knock-in mice. In addition, we found that the AR associates with
mitochondria in cultured cells. This study thus provides evidence for mitochondrial dysfunction in SBMA
cell and animal models, either through indirect effects on the transcription of nuclear-encoded mitochondrial
genes or through direct effects of the mutant protein on mitochondria or both. These ﬁndings indicate poss-
ible beneﬁt from mitochondrial therapy for SBMA.
INTRODUCTION
Spinal and bulbar muscular atrophy (SBMA) results from the
expansion of a polyglutamine tract in the androgen receptor
(AR) (1). SBMA is one of at least nine diseases with polygluta-
mineexpansion,includingHuntington’sdisease(HD),dentator-
ubral–pallidoluysianatrophyandsixspinocerebellarataxias(2).
SBMAisX-linkedandfullyaffectsonlymales(1).Thepolyglu-
tamine expansion in the AR results in selective degeneration of
motor neurons in the brainstem and spinal cord (3,4). The clini-
calcharacteristicsofSBMAincludemusclecramps,slowlypro-
gressive extremity weakness, muscle atrophy, fasciculations,
dysphagia and signs of androgen insensitivity, such as gyneco-
mastia and reduced fertility (4,5).
The AR is a member of the nuclear receptor family and a
ligand-activated transcription factor (6). In its inactive state,
the AR is cytoplasmic and sequestered by heat shock proteins.
On ligand binding, it dissociates from the complex of heat
shock proteins and translocates to the nucleus where it binds
to speciﬁc DNA sequences and activates transcription (6).
The polyglutamine expansion in the AR likely confers a
toxic gain and also a partial loss of AR function (7,8). Aber-
rant interactions of the mutant AR with other proteins, includ-
ing transcriptional co-activators, result in transcriptional
dysregulation and neuronal toxicity (9,10). There is consider-
able evidence supporting ligand-dependent toxicity (11–15).
For example, reducing androgen levels in transgenic mice
rescues the motor impairment and increases survival (12,14).
These studies point to altered transcriptional regulation as a
disease mechanism, but they do not preclude the possibility
of toxicity in the cytoplasmic compartment. The speciﬁc
mechanism of SBMA remains unclear, and there is currently
no effective treatment.
Mitochondrial dysfunction has been implicated in various
neurodegenerative diseases, including Huntington’s disease
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ataxia (16–21). It is also known that transcriptional dysregula-
tion in the nucleus can affect mitochondrial turnover and oxi-
dative phosphorylation (22–24). Peroxisome proliferator-
activated receptor-g coactivator-1a (PGC-1a) and its
homolog, PGC-1b, are nuclear transcriptional co-activators
and important regulators of energy metabolism (23–26).
Recent studies in HD show altered PGC-1a to be a likely
link between transcriptional dysregulation and mitochondrial
defects (27,28). Currently, little is known about mitochondrial
involvement in SBMA. Previous studies in cell models suggest
alterations in mitochondrial distribution and sequestration of
nuclear-encoded mitochondrial proteins in mutant AR aggre-
gates (29,30).
In this study, we investigated whether mutant AR alters
mitochondrial function in models of SBMA. We found that
the expression of mutant AR in motor neuron-derived
(MN-1) cells and with doxycycline induction in pheochroma-
cytoma-derived (PC12) cells is associated with mitochondrial
membrane depolarization and increased reactive oxygen
species (ROS). Cyclosporine A (CsA) mitigates the membrane
depolarization, and the increase in ROS levels is blocked by
the antioxidants co-enzyme Q10 (CoQ10) and idebenone.
We also found that the mutant AR increases Bax protein
levels, and activates caspases 9 and 3. The activation of cas-
pases 9 and 3 is likely mediated by the mitochondrial tran-
sition pore. Moreover, we observed decreased levels of
PGC-1b and mitochondrial superoxide dismutase (SOD2) in
MN-1 cells and in the tissues of a knock-in mouse model of
SBMA. We also found in vitro evidence for association of
AR with mitochondria. At the ultrastructural level, this associ-
ation is greater with the AR containing the expanded repeat.
Taken together, our results implicate mitochondrial abnormal-
ities and redox imbalance in SBMA. This study provides evi-
dence that mitochondrial modulators and antioxidants may
have therapeutic value in SBMA.
RESULTS
Mutant AR activates the mitochondrial caspase pathway
Previous studies have shown that the expression of mutant AR
results in the activation of caspase 3 in motor neuron-like cells
(MN-1) (31–34). To investigate whether caspase 9, a mediator
of the mitochondrial caspase pathway and activator of caspase
3, is also involved in SBMA pathogenesis, we used MN-1
cells that stably express either normal (AR-24Q) or mutant
AR (AR-65Q) (35). We found that the ligand exposure
increases caspase 9 activity by 50+12% in AR-65Q cells
compared to AR-24Q cells (P   0.05) (Fig. 1A). Opening of
the mitochondrial transition pore (MTP) is involved in the
activation of caspase 9, and CsA inhibits opening of the
MTP (36). Therefore, we tested whether the caspase 9 acti-
vation observed in MN-1 cells expressing mutant AR could
be decreased by CsA. We found that the ligand-induced
increase in caspase 9 activity in AR-65Q cells is decreased
by 32+8% by treatment of the cells with CsA (P   0.05)
(Fig. 1A). As a positive control for caspase 9 inhibition, we
used the speciﬁc caspase 9 inhibitor Ac-LEHD-CHO. Next,
we asked whether caspase 9 is upstream of caspase 3 in
MN-1 cells expressing mutant AR. Although in this cell
model of SBMA caspase-3 activation is not ligand-dependent,
it is polyglutamine-dependent (Fig. 1B), which is consistent
with a previous report (31). Treatment of cells with another
caspase 9 inhibitor z-LEHD-FMK blocked the increase
in caspase 3 activity by 47%, indicating that the activation
of caspase 3 is at least in part due to caspase 9 activation
(Fig. 1B). To further test the hypothesis that the mitochondrial
caspase pathway is involved in SBMA, we examined whether
inhibiting the MTP abrogates caspase 3 activation using a
ﬂuorescent-based assay (MitoCasp). As a positive control for
this assay, we used staurosporine, an apoptotic inducer (Sup-
plementary Material, Fig. S1). We found that the increase of
29+4% (P   0.01) in caspase 3 activity observed in the
AR-65Q cells relative to the AR-24Q cells was blocked by
treating the cells with CsA (39+7%; P   0.01) (Fig. 1C).
Alterations in the pro-apoptotic proteins, Bax and Bad and
subcellular localization of cytochrome C are associated with
the caspase 9/caspase 3 cascade (37–39). Therefore, we
tested whether the expression of these markers of
mitochondria-dependent apoptosis is altered in MN-1 cells
expressing mutant AR. We found that the expression of
expanded polyglutamine AR in MN-1 cells increased the
levels of Bax protein by 15+3% (P   0.05) (Fig. 1D).
We did not detect any change in cytochrome C release
(Fig. 1E). As control for Bax levels and release of cytochrome
C, we used lysates of HeLa cells treated with staurosporine
(data not shown). It has previously been shown that the
pro-apoptotic protein Bad when phosphorylated remains inac-
tive and sequestered in the cytoplasm by the transcription
factor, 14-3-3. Upon the activation of the calcineurin
pathway, Bad is dephosphorylated and translocates to the
mitochondria where it inactivates the anti-apoptotic protein,
Bcl-xL and then activates caspase 9 (39–41). To test
whether Bad is activated in MN-1 cells expressing mutant
AR, we did immunoblotting in MN-1 total cell extracts for
phospho-Bad (Ser 136) and total Bad (Fig. 1F). We found
no difference in phosphorylated Bad in AR-65Q cells com-
pared to AR-24Q cells. Taken together, these results indicate
that mutant AR increases Bax levels and activates the mito-
chondrial caspase pathway independently of cytochrome C
release and dephosphorylation of Bad.
Mitochondrial mass and number are reduced in cells
expressing mutant AR
We next sought to determine whether cells expressing mutant
AR have mitochondrial abnormalities. We tested this in both
stable MN-1 cells and inducible PC12 cells expressing either
normal or mutant AR (Fig. 2A and B). We used a mitochon-
dria speciﬁc ﬂuorescent dye, MitoTracker Green FM, to
examine mitochondrial mass by ﬂow cytometry. This dye
localizes to mitochondria independent of the functional state.
We found that the ﬂuorescent signal was decreased by 43+
11% (P   0.01) and 6+1% (P   0.0001) relative to normal
cells in mutant MN-1 cells and PC12 cells, respectively.
There was no further decrease in percent mitogreen positive
cells upon the addition of ligands (Fig. 2A–B). As a positive
control, we used antimycin A, an inhibitor of complex III of
the electron transport chain, and we found that it decreases
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AR-65Q cells (Fig. 2A).
WeaskedwhethertheexpressionofmutantARinMN-1cells
affects mitochondrial morphology and number. We tested this
in MN-1 cells expressing AR-24Q (Fig. 2C) and AR-65Q
(Fig. 2D) by electron microscopy. We found that the
morphology of mitochondria in mutant MN-1 cells is altered,
as the mitochondria in the AR-65Q cells have vesiculated
cristae (Fig. 2D; arrowheads), whereas there are numerous
electron dense branched cristae in mitochondria of the
AR-24Q cells (Fig. 2D; arrows). Quantitative assessment
showed a 61+6% (P   0.01) decrease in total mitochondrial
number in AR-65Q cells compared to the AR-24Q cells
(Fig. 2E). This decrease was not exacerbated by exposure of
thecellstoligand.Togetherthesedataindicateapolyglutamine-
dependent decrease in mitochondrial mass and number.
Cells expressing mutant AR have decreased mitochondrial
membrane potential
Abnormalities in mitochondrial membrane potential (MtMP)
are associated with mitochondrial dysfunction through altera-
tion in bioenergetic function (42,43). To investigate whether
the activation of the mitochondrial caspase pathway and
reduced number of mitochondria observed in the AR-65Q
cells are associated with mitochondrial dysfunction, we exam-
ined the MtMP in MN-1 cells. We used the ratiometric cat-
ionic dye JC1, which localizes to the mitochondria, and
emits a ﬂuorescent signal that varies with the membrane
potential (44,45). To capture the heterogeneity of responses
across the cell population, we assessed the membrane potential
using a ﬂuorescent-activated cell sorter (FACS) (45). We
observed an increase (15+5%; P   0.05) in mitochondrial
Figure 1. Mutant AR activates the mitochondrial caspase pathway. (A) MN-1 cells expressing the normal and mutant AR were exposed to vehicle alone or
androgen ligand (R1881), with and without caspase 9 inhibitor (Ac-LEHD) or CsA. The AR-65Q cells had an increase in caspase 9 activity in the presence
of R1881. CsA and the caspase 9 inhibitor block this increase. (B) Caspase 3 activity was measured with a ﬂuorometric assay in the AR-24Q and AR-65Q
MN-1 cells. These cells were treated with vehicle alone, caspase 9 inhibitor (z-LEHD-FMK) or pan-caspase inhibitor (z-VAD). AR-65Q cells showed a
ligand-independent increase in caspase 3 activity. This increase is partially blocked by z-LEHD-FMK. (C) We measured caspase 3 activity with another ﬂuoro-
metric assay in MN-1 cells expressing AR-24Q and AR-65Q cells. The cells were treated with either vehicle or CsA. There was an increase in caspase 3 activity
in cells expressing the mutant AR. This increase is ligand-independent and partially blocked with CsA. The caspase activities are indicated as percent activity
relative to untreated AR-24Q (assigned as 100%) and normalized to total protein content. (D) Immunoblotting of MN-1 total cellular lysates shows increased Bax
relative to tubulin in AR-65Q cells. The ﬁrst lane shows vehicle-treated parental MN-1 cells. (E) Immunoblotting of MN-1 cells for cytochrome C in mitochon-
drial and cytosolic fractions show no change in cytochrome C release in AR-65Q cells relative to parental MN-1 or AR-24Q cells. The last lane shows HeLa cells
treated with staurosporine as a positive control. (F) Immunoblotting of MN-1 total cell lysates for phosphorylated Bad and total Bad. Quantitation showed no
change in the ratio of phosphorylated and total Bad in AR-65Q cells relative to AR-24Q cells. The graphs (A–C) show data representative of three experiments
each done in triplicate with the error bars indicating standard error of mean (SEM);  P   0.05.
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orescence) in the AR-65Q cells compared to AR-24Q cells
(Fig. 3A) and a 38+3% (P   0.05) increase in the PC12
cells expressing mutant AR (Fig. 3B). This depolarization
was further increased in the presence of the ligand in mutant
MN-1 (32+5%; P   0.05) and PC12 cells (46+15%; P  
0.01). CsA reversed the ligand-dependent depolarization in
both MN-1 and PC12 cells, suggesting involvement of the
MTP in this process (Fig. 3A and B). Assessment of the
MtMP using TMRM, another mitochondria speciﬁc potentio-
metric dye, yielded results consistent with the FACS analysis
using JC1 (data not shown). Together, these results suggest
that mutant AR causes membrane changes indicative of
mitochondrial dysfunction in an expanded polyglutamine-
dependent and ligand-dependent manner.
Increased reactive oxygen species in SBMA cell models
One of the downstream effects of mitochondrial dysfunction is
oxidative stress through the generation of ROS (46,47). We
assessed ROS using dihydrorhodamine 123 (DHR123), an
oxidation-sensitive ﬂuorometric dye that localizes tomitochon-
dria. Exposure of AR-65Q cells to R1881 increased ROS levels
by 20+2% (P   0.01) (Fig. 4A). Treatment of these cells with
Figure 3. Mutant AR is associated with decreased MtMP. (A) AR-24Q and
AR-65Q MN-1 cells and (B) differentiated AR-10Q and AR-112Q PC12
cells induced to express AR were exposed to vehicle alone, and ligand
(R1881 or DHT) or CsA or both. Using ﬂow cytometry, MtMP was measured
with a ﬂuorescent indicator of MtMP and expressed relative to the vehicle-
treated cells. Depolarization was signiﬁcantly greater in both AR-65Q MN-1
(A) and AR-112Q PC12 cells (B) compared to the respective normal AR
expressing cells. The depolarization is signiﬁcantly increased by the addition
of ligand to the mutant cells. In addition, CsA blocks this depolarization. The
histograms represent ﬁve (A) and two (B) independent experiments each done
in triplicate, with the error bars showing the SEM;  P   0.05.
Figure 2. Reduced mitochondrial mass and number in cells expressing mutant
AR. (A) AR-24Q and AR-65Q MN-1 cells and (B) differentiated AR-10Q and
AR-112Q PC12 cells left uninduced or induced to express AR were treated
with vehicle or the mitochondrial toxin, antimycin A for 48 h. The cells
were then stained with a ﬂuorescent marker and mitochondrial mass was ana-
lyzed by ﬂow cytometry. AR-65Q (A) and AR-112Q cells (B) have
ligand-independent decrease in mitochondrial mass. The data in both panels
were normalized to the respective vehicle treated normal cells (set as
100%). Shown are the mean + standard error of three experiments;  P  
0.05. (C and D) Representative high magniﬁcation (10 000 ) electron micro-
graphs of AR-24Q (C) and AR-65Q MN-1 (D) cells exposed to vehicle for
24 h. The micrographs show more mitochondria (arrows in B) in AR-24Q
compared to AR-65Q cells. The AR-65Q cells have vesiculated cristae (arrow-
heads in D). (E) The total number of mitochondria was counted in 10–12 cells
per sample. The error bars indicate SEM;  P   0.05.
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blocked this increase in ROS by 13+2% (P   0.01) and
18+1% (P   0.01), respectively. Similarly we observed a
57+13% (P   0.01) increase in ROS in mutant PC12 cells
exposed to ligand (Fig. 4B). CoQ10 and idebenone blocked
this increase in the mutant PC12 cells by 23+13% (P  
0.05) and 30+17% (P   0.05), respectively (Fig. 4B).
Mutant AR alters the expression of genes important
for mitochondrial function
We next investigated whether mitochondrial dysfunction is
associatedwithalteredexpressionofgenesrelatedtomitochon-
drial function in AR-24Q and AR-65Q MN-1 cells when
exposed to ligand (Fig. 5A). PGC-1 is a key regulator of mito-
chondrial biogenesis and function (26,48,49). We found that
PGC-1b mRNA was decreased by 48+10% (P   0.001) in
the presence of ligand in cells expressing AR-65Q relative to
cells expressing AR-24Q (Fig. 5A). Peroxisome proliferator-
activated receptor-g (PPARg) and mitochondrial transcription
factor A (Tfam) are two nuclear-encoded genes regulated by
PGC-1. The expression levels of PPARg and Tfam were down-
regulated by 40+10 and 59+7%, respectively, in the
ligand-exposed AR-65Q cells (Fig. 5A). Tfam in turn regulates
transcription of genes encoded by mitochondrial DNA, includ-
ing subunits of complexes of the electron transport chain. We
examined mRNA levels for the mitochondrial proteins NADH
dehydrogenase 1 and 5 (ND1 and ND5), which are subunits of
complex I, and cytochrome c oxidase I, II and III (COX I, II
and III), which are subunits of complex IV. ND1 mRNA
levels were signiﬁcantly decreased (64+13%; P   0.05) in
AR-65Q cells exposed to ligand, while expression of ND5,
COX I, II and III was unaltered (Fig. 5A). To further assess
whether the transcription of genes involved in redox balance
is affected in the ligand-exposed AR-65Q cells, we examined
the transcript levels of antioxidant genes. We quantiﬁed the
mRNA levels of SOD2 and other cellular antioxidants [SOD1,
catalase and glutathione peroxidase (Gpx1)] and found that
transcript levels of SOD1, SOD2 and catalase were reduced
by 42+6, 58+17 and 46+7%, respectively (P   0.05)
(Fig. 5A). Gpx1 mRNA levels were unchanged. In addition,
we found that ligand treatment did not alter transcript levels of
NF-E2-related factor-2 (Nrf2), a regulator of antioxidant
genes, and its targets, NAD(P)H:quinine oxidoreductase 1
(NQO1) and heme-oxygenase 1 (HO-1) (Fig. 5A). We veriﬁed
that the decrease in SOD2 transcription translates into protein
changes by immunocytochemistry (Supplementary Material,
Fig. S2A). We found a decrease in SOD2 staining
(FITC-labeled) in ligand-treated mutant MN-1 cells. As a mito-
chondrialmarker,weusedHsp60,andwefoundthattherewasa
decrease, consistent with reduced mitochondrial number or
mass (Supplementary Material, Fig. S2A).
We then examined the expression of these genes in muscles,
testis and spinal cord from a knock-in mouse model of SBMA
(Fig. 5B–G). We analyzed mRNA levels in pre-manifesting 1
month old (Fig. 5B, D and F) and weakness-manifesting 5
month old (Fig. 5C, E and G) mutant AR mice (AR-113Q),
and compared the results to mice expressing non-pathological
repeat length AR (normal AR mice; AR-21Q).
Notably, we found that in pre-manifesting mice, PGC-1b
mRNA was decreased by 68+3% (P   1   10
26), 36+
2% (P   1   10
26) and 17+3% (P   0.01) in hind limb
muscle (Fig. 5B), spinal cord (Fig. 5D) and testis (Fig. 5F),
respectively. The levels of PGC-1b mRNA remained
reduced in muscle and testis of 5 month old mice (Fig. 5C
and G). Moreover, we found that in 1 month old mutant
mice, SOD2 mRNA was reduced in muscle, spinal cord and
testis by 42+2% (P   1   10
210; Fig. 5B), 11+1% (P  
1   10
28; Fig. 5D) and 44+1% (P   1   10
28; Fig. 5F),
respectively. In 5 month old mutant mice, the SOD2 transcript
levels remained decreased by 20+2% (P   0.05), 19+3%
(P   0.05) and 50+3% (P   1   10
25) in muscle, spinal
cord and testis, respectively (Figs 5C, E and G). We examined
SOD2 protein levels in immunoblots of muscle and spinal cord
tissue lysates of pre-manifesting (1 month) and manifesting
(3 month) mice. We found decreased levels of SOD2 in
both muscle (Supplementary Material, Fig. S2B) and
spinal cord of 3 month old mice (Supplementary Material,
Fig. S2C).
Figure 4. Mutant AR increases ROS (A) AR-24Q and AR-65Q MN-1 cells
and (B) differentiated AR-10Q and AR-112Q PC12 cells induced to express
AR were exposed to vehicle alone, ligand (R1881 or DHT) and CoQ10 or ide-
benone. ROS levels were measured with a ﬂuorometric assay and are indicated
relative to vehicle-treated AR-24Q cells (A) or vehicle-treated cells induced to
express AR-10Q (B) (assigned as 100%). In both mutant MN-1 (A) and PC12
(B) cells, ROS levels increased with ligand and co-enzyme Q10 and idebenone
blocked this increase. The graph shows representative results of one of the
three independent experiments in (A), and the average of three experiments
in (B), which were each done in triplicate. The error bars indicate the SEM;
 P   0.05.
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reduced in spinal cord (31+3%; P   0.001) and testis
(20+2%; P   0.05) of mice at the pre-manifesting stage.
ND1 and ND5 mRNA levels were increased in all three
tissues in the 1 month old mice (Fig. 5B, D and F), but
decreased as the disease progressed (Fig. 5C, E and G). The
expression of Nrf2 and NQO1 was increased in the tissues
of 1 month old mice (Fig. 5B, D and F). There was little or
no change in PGC-1a, COX I, COX II, COX III, SOD1,
Gpx1 and HO-1 in muscle (Fig. 5B and C) and spinal cord
(Fig. 5D and E) of 1 and 5 month old mutant mice. In the
testis of 5 month old mutant mice, all the analyzed genes
had signiﬁcant reduction in mRNA levels, with the exception
of NQO1 and catalase, which were unaltered (Fig. 5G).
Altered subcellular distribution of androgen receptor
We hypothesized that the mitochondrial abnormalities found
in cells expressing mutant AR may be due in part to direct
association of mutant AR with mitochondria. To test this,
Figure 5. Mutant AR alters expression of genes important for mitochondrial function. Total RNA from MN-1 cells (A), and hind limb muscle (B and C), spinal
cord (D and E) and testis (F and G) of mice expressing AR-21Q, and AR-113Q was analyzed by quantitative RT–PCR as described in Materials and Methods.
All transcript levels were normalized to the loading control, S18. (A) Gene expression of R1881-exposed MN-1 cells is shown relative to the respective vehicle
treated controls (assigned as 1). (B–G) Transcript levels of pre-manifesting (B, D, F) and manifesting (C, E, G) AR-113Q mouse muscle (B, C), spinal cord (D,
E) and testis (F, G) are shown relative to transcript levels in AR-21Q mice (assigned as 1). All experiments were done in triplicate, with the error bars indicating
SEM;  P   0.05,   P   0.01,    P   0.001 and     P   0.0001.
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and PC12 cells (Fig. 6D–E). We found that AR with normal
(24Q) and expanded (65Q) polyglutamine localized to the
cytosolic (Fig. 6A), mitochondrial (Fig. 6B) and nuclear frac-
tions (Fig. 6C). To conﬁrm the efﬁcacy of the fractionation
and purity of the lysates, we probed for tubulin, porin and
HDAC1 as markers of cytosol, mitochondria and nucleus,
respectively. As further conﬁrmation of the purity of these
fractions, we detected SOD2 and complex IV only in the mito-
chondrial fractions.
To examine the exact localization of AR in mitochondria,
we did ultrastructural studies using transmission electron
microscopy (Fig. 6F and G). Immunogold labeling for AR in
MN-1 cells showed that AR localized within the organelle
as well as along the membrane. Quantitative assessment
showed an increased number of AR-positive mitochondria
(56+3%; P   0.001) in the AR-65Q MN-1 cells compared
to AR-24Q cells (Fig. 6H). Thus, the results from both subcel-
lular fractionation and ultrastructural studies indicate that AR
associates with mitochondria.
Attenuation of cell death in MN-1 cells with
mitochondrial modulators
We then investigated whether CsA and antioxidants rescue
mutant AR-induced cell death, using loss of membrane integ-
rity as a measure of cell viability. We observed that the
increase of 61+11% (P   0.01) caused by the expression
of mutant AR in MN-1 cells was mitigated by CsA (21+
4%; P   0.01), CoQ10 (31+6%; P   0.01), idebenone
Figure 6. Altered subcellular distribution of androgen receptor. Cytosolic (A and D), mitochondrial (B and E) and nuclear (C) fractions were probed for AR in
vehicle-treated and R1881-exposed parental, AR-24Q and AR-65Q MN-1 cells (A–C) and in differentiated vehicle-treated PC12 cells (D and E). To conﬁrm the
purity of the fractions, we used antibodies for tubulin (cytosol), porin (mitochondria) and HDAC1 (nucleus). HDAC1 and tubulin were not detected in the mito-
chondrial fractions, and porin was not detected in the cytosolic and nuclear fractions (latter not shown). Heart mitochondrial lysate and knock-in mouse testis
tissue lysates were used as negative and positive controls for AR. The parental samples, which do not express AR, were also a negative control. Sample assign-
ments in the gels (A–C) are: lane 1, parental vehicle-treated MN-1; lane 2, vehicle-treated AR-24Q; lane 3, AR-24QþR1881; Lane 4, vehicle-treated AR-65Q;
lane 5, AR-65QþR1881; lane 6, heart mitochondrial lysate; lane 7, knock-in mouse testis tissue lysate. (D and E) Lane 1, vehicle-treated Dox-induced parental
cells; lane 2, vehicle-treated uninduced AR-10Q; lane 3, vehicle-treated Dox-induced AR-10Q; lane 4, Dox-induced AR-10QþR1881; lane 5, Dox-induced
AR-10QþDHT; lane 6, vehicle-treated uninduced AR-112Q; lane 7, vehicle-treated Dox-induced AR-112Q; lane 8, Dox-induced AR-112QþR1881; lane 9,
Dox-induced AR-112QþDHT; lane 10, human heart mitochondrial lysate. (F–H) Electron dense immunogold particles indicate AR in AR-24Q (F) and
AR-65Q (G) MN-1 cells exposed to vehicle alone. 10 000  electron micrographs (F and G) show mitochondria with (arrows) or without (arrowheads) associated
AR in AR-24Q (F) and AR-65Q cells (G). (H) The percentage of mitochondria with associated AR is higher in AR-65Q cells. The histogram represents averages
from 10 to 12 cells, with the error bars indicating SEM;  P   0.05.
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(26+9%; P   0.01) (Fig. 7A). Although ligand-dependent
toxicity has been found in other models of SBMA, we found
that exposure of the cells stably expressing AR-65Q to
ligands did not exacerbate cell death (data not shown).
However, when mutant AR expression was induced in PC12
cells, ligand exposure increased cell toxicity by 43+10%
(P   0.01) (Fig. 7B). The ligand-dependent toxicity was
reversed by z-VAD (53+7%; P   0.001), CoQ10 (65+
7%; P   0.001), idebenone (55+11%; P   0.001) and CsA
(56+10%; P   0.001). Staurosporine, an apoptotic inducer,
increased cell death by 3-fold (data not shown).
In conclusion, we show that mitochondrial number and
function are altered in cell models of SBMA. Treatment of
the cells with CsA and antioxidants rescues cells from the tox-
icity induced by mutant AR. Therefore, we propose that mito-
chondrial dysfunction is at least in part responsible for the
toxicity of mutant AR in SBMA.
DISCUSSION
Mitochondrial abnormalities and oxidative stress-mediated
neuronal toxicity have been implicated in many neurodegen-
erative diseases, including ALS and HD (16,18,19,50,51).
Here we studied mitochondrial dysfunction in SBMA. We
found that the expression of mutant AR is associated with acti-
vation of the mitochondrial caspase pathway, decreased
MtMP, elevated ROS levels and increased cell death. These
changes were mitigated with CsA and antioxidants. We also
report consistent decreases in PGC-1b mRNA and in SOD2
mRNA and protein. Altered gene expression in a knock-in
mouse model of SBMA was evident in pre-manifesting
mice, suggesting that mitochondrial abnormalities and redox
imbalance occur early in the disease mechanism. Interestingly,
we found AR associated with the mitochondria in MN-1 and
PC12 cells. Taken together, the evidence supports both indir-
ect and direct effects of mutant AR on mitochondrial function
in SBMA (Fig. 8).
SBMA is characterized by both a loss of normal AR func-
tion and a toxic gain of function. It is well established that
there is transcriptional dysregulation due to partial loss of
AR function and to ligand-dependent toxicity (9,10,12–14).
The effects of mutant AR on mitochondrial function that we
found were both ligand-dependent and -independent. Although
previous studies identiﬁed gene expression changes in the pre-
sence of mutant AR (52), transcriptional effects on either
nuclear-encoded mitochondrial genes or transcription of the
mitochondrial DNA have not previously been reported. It is
likely that mutant AR alters the expression of mitochondrial
genes, and this in turn may affect mitochondrial turnover
and respiratory function. The nuclear co-activator, PGC-1, is
known to regulate mitochondrial biogenesis and function
(23,49,53). PGC-1a knock-out mice have impaired energy
homeostasis, hyperactivity, striatal degeneration and beha-
vioral changes characteristic of movement disorders, including
HD (54). PGC-1a and b regulate oxidant-detoxifying enzymes
and also the expression of mitochondrial transcription factor A
(Tfam), a direct regulator of mitochondrial DNA replication
and transcription (53,55). We could not detect the expression
of PGC-1a in MN-1 cells, but transcript levels of its isoform
PGC-1b and Tfam were signiﬁcantly decreased, and this
could account for the reduced mitochondrial number and
membrane potential that we observed. In addition, expression
of cellular antioxidants, such as SOD2, was altered in MN-1
cells, consistent with increased oxidative stress. In pre-
manifesting (1 month old) SBMA knock-in mice, we found
alterations in transcripts that regulate mitochondrial biogenesis
(PGC-1a, PGC-1b and Tfam), metabolism (subunits of
complex I and IV that are encoded by the mitochondrial
DNA) and antioxidants. This indicates that mitochondrial
alterations and oxidative imbalance are early and important
events in SBMA. It is also noteworthy that the transcript
levels of ND1 and ND5 are decreased concurrent with
decreased PGC-1b and Tfam in the manifesting (5 month
old) SBMA mice. This suggests that the metabolic demand
increases in the tissues of this mouse model as the disease pro-
gresses. Also, consistent with the previously reported patho-
logical ﬁndings (56,57), the greatest changes occurred in
muscle and testis early in the disease and persisted as the
Figure 7. Cell death in AR-65Q MN-1 cells and AR-112Q PC12 cells is atte-
nuated by treatment with mitochondrial modulators. (A) AR-24Q and AR-65Q
MN-1 cells were analyzed for cell toxicity by propidium iodide staining and
FACS. Relative to the AR-24Q cells (assigned as 100%), the vehicle-treated
AR-65Q cells had increased toxicity. This increase was attenuated by treat-
ment with CsA, CoQ10, idebenone and z-VAD. The histogram represents
two experiments each done in triplicate, with error bars indicating the SEM;
 P   0.05. (B) Differentiated PC12 cells induced to express AR-10Q and
AR-112Q were exposed to vehicle control, R1881, the pan-caspase inhibitor,
z-VAD, CoQ10, idebenone or CsA were analyzed for cell toxicity by propi-
dium iodide staining and FACS. Vehicle-treated AR-112Q cells did not
show toxicity relative to the vehicle-treated AR-10Q cells (assigned as
100%). PC12 cells expressing AR-112Q cells exposed to R1881 had increased
cell toxicity. This increase was attenuated by treatment with CsA, CoQ10, ide-
benone and z-VAD. The histogram represents three experiments each done in
triplicate, with error bars indicating the SEM;  P   0.001.
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examine whether mutant AR alters bioenergetics and
whether it does so by indirectly or directly affecting the
activity of the electron transport chain and ATP levels.
Previous studies have shown the localization of steroid and
thyroid hormone receptors to mitochondria (58–61). Hormone
response elements in the mitochondrial genome and metabolic
effects of glucocorticoids and estrogens suggest a direct action
of these hormones on mitochondria (62). We are unaware of
previous reports of normal or mutated AR localized to neur-
onal mitochondria. We found mitochondria-associated AR in
MN-1 cells, which have constitutive expression of AR, and
also in the inducible PC12 cells that express normal and
mutant AR at comparable levels. This supports the conclusion
that the association is not simply due to clonal variation or
differences in the relative levels of AR expression. Although
the association of AR with mitochondria that we found is
not limited to the mutant form, it is likely that the presence
of the expanded polyglutamine-containing AR directly
confers a toxic gain of function resulting in mitochondrial
abnormalities and oxidative imbalance. These results suggest
that the mitochondrial defects may be due to both transcrip-
tional events mediated by the nucleus and a direct toxic
effect of the mutant AR on the mitochondria. The mutant pro-
teins that cause HD and spinocerebellar ataxia 3 have also
been reported to associate with mitochondria (20,63)
suggesting that the mitochondrial association of the mutant
proteins in polyglutamine expansion diseases may point
towards a common pathogenic mechanism. Our ﬁnding that
AR localizes to mitochondria in both MN-1 and PC12 cells
may have important implications in understanding normal
AR function and its role in disease.
It has not previously been well documented that mutant AR
affects mitochondrial number and function. However, it has
been reported in other neurological disorders that excito-
toxicity and other insults cause mitochondria to undergo ves-
iculation of the cristae, vacuolation and fragmentation
(51,64–66). Although in our study we cannot deﬁnitively
demonstrate fragmentation, our results do indicate that the
expanded polyglutamine in AR alters mitochondrial number
and morphology of the cristae. The reduced number of mito-
chondria in PC12 cells induced to express mutant AR indicates
that the decrease in MN-1 cells is not simply an adaptive
change related to constitutive expression of the mutant
protein. Mitochondrial number can be affected by differences
in cellular proliferation or passage numbers of the clones.
However, the different experimental conditions did not
induce any variation in cellular proliferation, and we con-
trolled for possible differences due to different passage
numbers of the different clones. The vesiculation and vacuo-
lation that we observed in the AR-65Q cells could be due to
mitochondrial toxicity or vice versa. The mitochondrial mem-
brane depolarization and the response to CsA treatment in the
in vitro models of SBMA are further evidence for the role of
mitochondrial dysfunction and the MTP in SBMA. The pro-
tective effect of CsA suggests but does not prove the involve-
ment of the MTP, because CsA also has other effects, such as
calcineurin inhibition (67). The effects we found on MtMP
were both ligand-dependent and -independent. In light of
these results, the effects of the mutant AR on mitochondrial
mass, number and membrane potential may be due either to
indirect nuclear-encoded transcriptional effects on mitochon-
dria or to direct toxic interactions of the expanded polygluta-
mine with mitochondria. However, these are not mutually
exclusive, as the disease mechanism could involve a combi-
nation of both effects.
Regardless of the cause of mitochondrial dysfunction, we
found that the effects of the mutant AR include increased
ROS, increased Bax protein levels, activation of caspases 9
and 3 and increased cell death. The mitochondrial abnormal-
ities described in this study may be an important modiﬁer of
the pathogenic process, where the ligand-dependent effect of
the mutant AR on transcription is likely to be exacerbated
by a direct effect on mitochondria. The mitochondrial dys-
function may then tip the cell towards the activation of the
caspase cascade and death. Alterations in oxidative phos-
phorylation may result in the generation of ROS and elevated
oxidative stress (21,68). Also, increased ROS generation may
further damage mitochondria. In vivo deletion of SOD2 in
mice results in mitochondrial pathology and shortens lifespan
(69). In another study, partial reduction of SOD2 in hAPP
transgenic mice accelerates the onset of b amyloid-induced
behavioral impairment and signiﬁcantly worsens Alzheimer’s
disease pathology (70). We did not see a general decrease in
transcript levels of cellular antioxidants, but the mitochondrial
antioxidant, SOD2, was speciﬁcally and consistently reduced
in all three affected tissues, indicating the importance of
mitochondria-associated oxidative stress in SBMA. This oxi-
dative imbalance can further result in mitochondrial mem-
brane changes that initiate the intrinsic caspase cascade
Figure 8. Mechanism of mitochondrial dysfunction in SBMA. Mitochondrial
mass, number and membrane potential are likely affected by mutant AR
indirectly through ligand-dependent alterations in mitochondrial gene
expression and directly through association of AR with mitochondria. The
decrease in MtMP is blocked by CsA. Downstream from the mitochondrial
dysfunction, mutant AR increases ROS levels, which can reversibly result in
further deleterious effects on the mitochondrial membrane. The antioxidants
CoQ10 and idebenone block the increase in ROS levels. Mitochondrial dys-
function increases caspase 9 activity, which in turn increases caspase 3
activity. Elevated ROS levels and caspase 3 activation result in cell death.
Activation of the caspases is mitigated by CsA, and cell death is attenuated
by CsA, CoQ10, idebenone and the caspase inhibitor, z-VAD. Thus, regardless
of the cause of mitochondrial dysfunction, downstream events may be targets
for therapeutic intervention, for example with CsA and antioxidants.
Human Molecular Genetics, 2009, Vol. 18, No. 1 35involving activation of caspases 9 and 3. Our results support
cytochrome C release- and Bad-independent activation of
caspase 9, consistent with previous reports of cytochrome C
independent activation of caspase 9 (71–74). In addition our
ﬁndings that the increase in Bax and caspase 3 activation is
polyglutamine-dependent while caspase 9 activation is ligand-
dependent also suggest involvement of other pathways in the
activation of caspase 9. Post-translational modiﬁcations such
as phosphorylation or the release of Smac/Diablo can
mediate caspase 9 activation. Further studies of these path-
ways in cell culture and mouse tissues may be warranted.
The ﬁnding that CsA mitigates MtMP changes and the acti-
vation of caspases 9 and 3 indicates that the expression of
the mutant AR is associated with mitochondrial dysfunction,
which can be reversed by pharmacological intervention.
Importantly, treating these cells with antioxidants was effec-
tive not only in mitigating the increase in ROS but also in
blocking cell death caused by the expression of mutant AR.
While cell death in the MN-1 cells was dependent on
mutant polyglutamine but not ligand, the toxicity of mutant
AR in PC12 cells was ligand-dependent. With constitutive
expression of AR-65Q, the mutant MN-1 clone may have
adapted to cope with ligand-dependent effects. These in
vitro studies warrant follow-up studies in tissue mitochondria
and pre-clinical therapeutic studies of antioxidants in SBMA
mouse models.
While we do not differentiate between primary and
secondary roles of mitochondrial defects in SBMA pathogen-
esis, we propose that mitochondrial dysfunction and dysregu-
lation of the antioxidant defense are important in the disease
mechanism. Given the central role of mitochondrial integrity
in bioenergetics and cell death pathways, improvement of
mitochondrial function is worth considering as a therapeutic
approach to SBMA.
MATERIALS AND METHODS
Reagents
All cell culture reagents were purchased from Invitrogen
(Gaithersburg, MD) unless otherwise mentioned. The non-
aromatizable synthetic ligand R1881 and the natural ligand
dihydrotestosterone were purchased from Sigma-Aldrich (St
Louis, MO, USA). 5,50,6,60-tetrachloro-1,1,3,3-tetraethylben-
zimidazolcarbocyanine iodide (JC-1), tetramethyl rhodamine
methyl ester (TMRM), MitoTracker Green FM and DHR
123 were obtained from Molecular Probes (Gaithersburg,
MD, USA). The other compounds used in the study were
nerve growth factor (NGF; BD Biosciences), doxycycline
(Dox) (Sigma), CsA (Sigma), co-enzyme Q10 (CoQ10)
(Sigma), idebenone (Santhera Pharmaceuticals, Switzerland),
puriﬁed caspase 9 enzyme and caspase 9 inhibitor (Ac-
LEHD-CHO; BIOMOL), caspase 9 inhibitor (z-LEHD-FMK;
Alexis Biologicals), pan-caspase inhibitor (z-VAD-FMK; BD
Pharmingen), staurosporine (STS; Calbiochem), p-
triﬂuoromethoxy carbonyl cyanide phenyl hydrazone (FCCP;
Sigma), antimycin A (Sigma), hydrogen peroxide (Fisher
Scientiﬁc) and propidium iodide (PI; Sigma).
Cell culture
Stably transfected mouse spinal cord motor neuron-derived
hybrid (MN-1) cells and stably transfected inducible rat pheo-
chromacytoma (PC12) cells of SBMA were cultured as pre-
viously described (15,35). The PC12 cells were provided by
Dr Diane Merry (Thomas Jefferson University, PA, USA).
MN-1 cells were maintained in normal growth medium
(Dulbecco’s Modiﬁed Eagle’s Medium) with 10% fetal
bovine serum (FBS; Atlanta biologicals, GA, USA), 2 mM
L-glutamine and 100 units/ml penicillin/streptomycin at 378C
in 5% CO2. The MN-1 clones constitutively expressing
either the full-length wild-type AR with 24 glutamines
(AR-24Q) or the full-length mutant AR with 65 glutamines
(AR-65Q) were grown in the same medium supplemented
with 350 mg/ml G418. It has been demonstrated that in the
absence of ligand, the mutant protein is expressed at lower
levels than the wild-type protein (35). The steady-state
levels of both forms of the protein are increased with the
addition of ligands (52). We used DHT, the natural ligand
and R1881, the synthetic non-metabolizable ligand for our
experiments. We did not see any difference in the effects of
DHT and R1881 at the concentrations used in this study.
The parental PC12 cells were grown on rat tail collagen
I [0.01% w/v in 0.1 M glacial acetic acid / 1X phosphate-
buffered saline (PBS)] coated dishes. Cells were cultured in
DMEM with 10% heat inactivated horse serum (HyClone,
UT), 5% tetracycline-negative FBS (Tet- FBS; Clontech,
CA, USA), 1 mM sodium pyruvate, 2 mML -glutamine, 100
units/ml penicillin/streptomycin, 200 mg/ml hygromycin B
(complete medium) at 378C in 10% CO2. The AR-10Q and
AR-112Q PC12 clones were maintained in the complete
medium supplemented with 100 mg/ml G418. PC12 cells
were differentiated with 200 ng/ml NGF for 1 day and all
experiments were done while maintaining the cells in a differ-
entiated state. The MN-1 cells were not differentiated. All
experiments in MN-1 and PC12 cells were done in complete
medium containing 10% charcoal dextran stripped
(CDSFBS) (HyClone, UT, USA). The experiments with
PC12 cells were done in complete medium but replacing the
Tet- FBS with CDSFBS and in the presence of 200 ng/ml
NGF. The cells were either left uninduced or induced with
10 ng/ml of Dox. Unless otherwise mentioned, cells were
treated with 10 nM R1881, 10 nM DHT, 250 nM CsA, 200 nM
CoQ10, 200 nM idebenone, 10 mM FCCP, 250 nM
Ac-LEHD-CHO, 10 mM z-LEHD-FMK, 5 mM z-VAD for
either 24 or 48 h. As positive controls for different assays,
we used the mitochondrial toxin, antimycin A (200 or
500 ng/ml), hydrogen peroxide (500 nM) and the apoptotic
inducer, staurosporine (1 mm) for 16–18 h and 4 h,
respectively.
Mouse model
The generation and characterization of the knock-in mouse
model of SBMA (AR-21Q and AR-113Q) has been previously
described (56,57). Breeder mice were provided by Drs A.P.
Lieberman and D. Robins (University of Michigan, MI,
USA). The colonies of mice with the non-pathological
repeat length of glutamines knocked in the AR (AR-21Q;
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with 113 glutamines knocked in the AR (AR-113Q; mutant)
males are infertile and hence the mutant mice colonies were
maintained by mating females heterozygous for the targeted
allele with wild-type C57BL/6J males. All experiments were
carried out in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals,
and were approved by the National Institute of Neurological
Disorders and Stroke Animal Care Committee. Tail DNA gen-
otyping was done using the REDExtract-N-AMP tissue PCR
kit (Sigma). The primers used for the genotyping were
50-ggaagtgcagttagggctggga and 50-gacactgccttacacaactccttggc.
For biochemical studies, mice were anesthetized with iso-
ﬂurane and sacriﬁced by cervical dislocation. Spinal cord,
hind limb skeletal muscle and testes were dissected and snap
frozen in liquid nitrogen. The tissues were stored at 2808C
and thawed on ice immediately prior to RNA and protein
extraction.
Caspase 9 and caspase 3 assays
Caspase 9 activity was assessed with the Caspase-Glo 9 assay
as per the manufacturer’s protocol (Promega). MN-1 cells
were seeded in 24-well plates at 6   10
4 cells/well. Cells
were exposed to vehicle alone or androgen ligands (R1881
or DHT), and treated with or without caspase 9 inhibitor
(Ac-LEHD-CHO; Biomol) and CsA. After 48 h, cells were
trypsinized and centrifuged at 800g for 5 min. The cell
pellets were washed in 1X PBS and re-suspended in 200 ml
of 1X PBS. Half of the cell suspension was transferred to a
96-well plate for the luminescence assay and the other half
of the suspension was used to determine total protein concen-
tration. Puriﬁed caspase 9 enzyme (100 units/ml) was used as
a positive control, and the vehicle control was used as a blank
for the assay. Caspase-Glo 9 reagent (100 ml) was added to
each sample in the 96-well plate; the samples were incubated
for 1 h at room temperature and luminescence measured with a
Victor
3 multi-well luminometer (Perkin Elmer, MA, USA).
The luminescence is a direct measure of the caspase 9 activity
and was normalized to total cellular protein. An equal volume
of the Mammalian Protein Extraction Reagent (M-PER; Pierce
Biotechnology) was added to the 100 ml cell suspension to
lyse the cells, and following centrifugation at 800g for 7 min
the lysate was used to determine the protein concentration
by the MicroBCA Protein Assay method as per manufacturer’s
protocol (Pierce Biotechnology).
Caspase 3 activity was measured with two different assays.
In the ﬁrst, caspase 3 activity was determined by the ApoTar-
get ﬂuorometric assay (Biosource International) according to
manufacturer’s instructions and a published protocol (31).
Another caspase 9 inhibitor (z-LEHD-FMK) and pan-caspase
inhibitor (z-VAD) were used at concentrations of 10 and 5 mM,
respectively. Protein concentrations were estimated on parallel
samples using the bicinchoninic acid protein assay method.
In an independent caspase 3 assay, the activity was
measured with MitoCasp (Cell Technology, CA, USA) as
per manufacturer’s instructions. Brieﬂy, cells grown in
24-well dishes and treated for 48 h were stained with the
MitoCasp reagents for 1 h at 378C. After PBS washes and
centrifugation, the re-suspended pellets were transferred to a
black-wall 96-well plate. The caspase 3 activity was deter-
mined with a ﬂuorescent-based assay wherein carboxyﬂuores-
cein (FAM)-labeled ﬂuoromethyl ketone (FMK)-peptide
inhibitors bind to active caspases and ﬂuoresce green (emis-
sion peaks at 510 nm). The ﬂuorescence was measured in a
Victor
3 multi-well plate ﬂuorometer and was normalized to
total protein content as described earlier (see caspase 9 activity
assay).
Mitochondrial mass
MN-1 and PC12 cells were seeded at 2.5   10
5 and 3   10
5
cells/well, respectively, in 6-well dishes. Following 48 h
exposure to vehicle or androgen ligands, the cells were
stained with 100 nM MitoTracker Green FM (MTG) in com-
plete medium prepared using phenol-red free DMEM for
30 min at 378C (75). After trypsinizing the adherent cells,
they were centrifuged at 800g for 5 min at room temperature.
The pellets were washed twice in PBS supplemented with
0.5% FCS and re-suspended in 400 ml PBS/0.5% FCS.
Green ﬂuorescent cells were analyzed by ﬂow cytometry
(Becton Dickinson FACS Calibur) using 488 nm laser exci-
tation and 530/30 nm MTG emission and Cell Quest software
(Becton Dickinson). A total of 100,000 cells were analyzed in
each sample. Cell populations were gated by size (forward
scatter) and granularity (side scatter) to exclude debris and
cell clumps for all samples. An unstained negative control
sample and a positive control sample of normal cells stained
with the MTG were used to establish a 100% positive refer-
ence region. Experimental samples stained with MTG were
then evaluated for the percent green ﬂuorescent cells in the
reference region.
Mitochondrial membrane potential (MtMP)
MtMP was determined as per published protocols (45,76). The
lipophilic cation JC-1 was used to obtain ratiometric determi-
nants of membrane potential using ﬂow cytometry (Becton
Dickinson FACS Calibur) and Cell Quest software (Becton
Dickinson). Lower potential causes JC1 to remain in a mono-
meric form with low amounts in the mitochondria and ﬂuor-
esce green. In contrast, when the mitochondrial membranes
are energized, the dye forms J-aggregates, accumulates in
the mitochondria and ﬂuoresces red. MN-1 and PC12 cells
were seeded at 2   10
5 and 3   10
5 cells/well, respectively,
in 6-well dishes. The cells were exposed to vehicle alone or
androgen ligands with or without 250 nM CsA for 48 h. As a
positive control, cells were exposed to 10 mM FCCP for
24 h. Cells were then stained with 5 mM JC-1 in complete
medium prepared with phenol-red free DMEM for 40 min at
378C. Adherent cells were collected by trypsinization and cen-
trifuged at 800g for 5 min at room temperature. The pellets
were then washed twice in PBS supplemented with 0.5%
FCS and re-suspended in 400 ml PBS/0.5% FCS before analy-
sis by ﬂow cytometry. A total of 50,000 cells were analyzed.
The degree of mitochondrial membrane depolarization was
calculated as the ratio of depolarized (green) to polarized
(red) signals from the dot plots.
In an independent assay, MtMP was determined using the
ﬂuorochrome TMRM, which localizes to mitochondria and
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number of mitochondria, as measured with MTG, which
labels all mitochondria irrespective of their functional state
(76). The ratio between TMRM and MTG ﬂuorescence indi-
cates MtMP normalized to the number of mitochondria.
Brieﬂy, cells in 6-well dishes were exposed to vehicle alone,
or to androgen ligands (R1881 and DHT), or treated with
250 nM CsA for 48 h. As a positive control for membrane
depolarization, cells were exposed to the mitochondrial uncou-
pler, FCCP (10 mM) for 24 h. They were then stained with
100 nM each of TMRM and MTG for 30 min at 378C. Follow-
ing trypsinization and centrifugation, the cells were washed
twice with PBS to remove excess ﬂuorochrome, re-suspended
in 1X PBS and gently lysed with 1% (v/v) Triton X-100. The
relative ﬂuorescence for TMRM (excitation, 550 nm; emis-
sion, 590 nm) and MTG (excitation, 405 nm; emission,
515 nm) was measured using the Victor (3) multi-well plate
ﬂuorometer.
ROS assay
ROS levels were measured in cell lines using ﬂuorescence-
based assays. MN-1 and PC12 cells were seeded at 6   10
4
and 1   10
5 cells/well, respectively, in 24-well dishes. These
cells were either exposed to vehicle or androgen ligands for
48 h. As positive controls, the cells were treated for 16 h
each with 200 ng/ml antimycin A, and 500 nM hydrogen per-
oxide. They were also treated with 200 nM each of the anti-
oxidants CoQ10 and idebenone. After 48 h of treatment, the
cells were loaded with the probe, DHR 123 at a ﬁnal concen-
tration of 5 mM. DHR 123 is an oxidation-sensitive lipophilic
dye that enters a cell, localizes to the mitochondria and ﬂuor-
esces when oxidized by mitochondrial ROS to positively
charged derivatives. Cell ﬂuorescence with a peak emission
of 530 nm was measured in lysed cells using a Victor
3 multi-
well plate ﬂuorometer. The relative ﬂuorescence units (RFU)
were normalized to total protein content, which was deter-
mined as for the caspase assays described earlier.
RNA isolation and quantitative real-time polymerase
chain reaction (qRT–PCR)
Total RNA was isolated from MN-1 cells (1   10
6) exposed to
vehicle control or the androgen ligands (16–24 h) and from
about 40–60 mg of mouse tissues as per a previously pub-
lished protocol (77). Brieﬂy, the RNA was extracted using
TRIzol (Invitrogen) and further puriﬁed using the RNAeasy
clean-up kit according to the manufacturer’s protocol
(QIAGEN). Isolated RNA was ﬁrst reverse transcribed to
cDNA using random hexamer primers with the High Capacity
cDNA Archive kit (Applied Biosystems, CA, USA). The
qRT–PCR reactions were performed in triplicate with
SYBR Green PCR core reagents using the ABI Prism 7900
Sequence Detector System (Applied Biosystems). Each of
the primer sets demonstrated ampliﬁcation, with no ampliﬁca-
tion of the negative controls. Since SYBR Green can bind
primer dimers and produce non-speciﬁc signal, melting
curves were generated for all primer sets in all experiments
to ascertain speciﬁcity of ampliﬁed products. Target gene
primer pairs are listed in Supplementary Material, Table S1.
cDNA transcribed with known concentrations of RNA was
diluted at 2-fold series to generate a standard curve for each
primer set according to the cycle of threshold value obtained
from real-time PCR. Primer efﬁciencies were estimated from
the standard curves. Based on the standard curves, we used
300 nM each of the forward and reverse primers and 3 ng of
the template for all experiments. Transcript levels were nor-
malized to the loading control, S18 rRNA. Relative gene
expression was determined by the Pfafﬂ method (78). The par-
ental MN-1 cells, vehicle treated AR-24Q and AR-65Q clones
were set to 1. The transcript levels of ligand-exposed AR-24Q
and AR-65Q cells were compared to the respective vehicle
treated samples. In the analysis of the knock-in mice, the non-
pathological (AR-21Q; normal) and pathological (AR-113Q;
mutant) samples were normalized to the AR-113Q wild-type
littermates. Gene expression in the AR-113Q mice was calcu-
lated relative to that of the AR-21Q mice, which was assigned
as 1. For the study, we used 1 month and 5 month old mice,
and all experiments were conducted at least twice with each
condition in triplicate. The numbers of 1 month old (pre-
manifesting) and 3–5 month old (manifesting) mice used in
the study were as follows: AR-21Q 1 month (n ¼ 10) and
3–5 month old (n ¼ 7); AR-113Q mutant 1 month (n ¼ 9)
and 3–5 month old (n ¼ 4); AR-113Q wild type littermates
1 month (n ¼ 6) and 3–5 month old (n ¼ 7).
Immunocytochemistry and confocal microscopy
MN-1 cells were seeded in two-chamber CC2-coated slides
(Lab-Tek; NUNC) at 10
5 cells/well and exposed to vehicle
control or R1881 for 48 h. They were then ﬁxed in ice cold
4% paraformaldehyde at room temperature for 20 min, per-
meabilized with 0.1% Triton X-100 in PBS for 15 min and
blocked with 5% normal goat serum for 1 h. The samples
were incubated with polyclonal antibodies to SOD2 (4 mg/
ml; SOD-110, Stressgen) and Hsp60 (1:150; Santa Cruz Bio-
technology). Following washes in 1X PBS, they were incu-
bated with FITC and Texas red conjugated secondary
antibodies (Jackson Immuno-Research Laboratories), washed
and mounted using DAPI-containing Vectashield mounting
media (Vector Labs). Deconvoluted images were acquired
with a Zeiss LSM510 laser scanning confocal microscope.
Total cell protein extraction, sub-cellular fractionation
and immunoblotting
MN-1 and PC12 cells were seeded in 10 cm dishes at 8   10
5
and 1   10
6 cells/dish, respectively. They were exposed to
vehicle alone or the androgen ligands for 48 h. The cells
were then trypsinized and centrifuged at 800g for 7 min, and
the pellets were washed twice in cold 1X PBS. For total cell
lysates, the pellets were re-suspended in 200 ml lysis buffer
(0.01 M sodium phosphate, pH 7.2, 0.15 M NaCl, 0.1%
sodium dodecyl sulfate, 1% sodium deoxycholate, 1% NP40
and 2 mM EDTA) with a protease inhibitor cocktail (Roche
Diagnostics) and incubated on ice for 10 min. The lysates
were then sonicated for 10 s and microfuged at 20 000g for
10 min at 48C. The supernatant was then collected as the
total cell lysate. Total tissue homogenate was prepared by
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protein extracted following the protocol as described above.
Mitochondrial subcellular fractions were prepared from
cells using the mitochondrial isolation reagents (Sigma) as
per the manufacturer’s protocol. Brieﬂy, cells suspended in
extraction buffer were homogenized in a Dounce homogenizer
using 15 strokes. The samples were then microfuged at 1000g
for 5 min at 48C. The supernatant was transferred to a fresh
tube and centrifuged at 3500g for 10 min at 48C. The resulting
supernatant was stored as the cytosolic fraction. The pellet was
re-suspended in 100 ml CelLytic M cell lysis reagent (Sigma)
and stored as the mitochondrial fraction. Nuclear fractiona-
tions were prepared using the NE-PER nuclear and cyto-
plasmic extraction reagents (Pierce Biotechnology) following
the manufacturer’s instructions. Total protein concentrations
of all preparations were determined with the BCA protein
assay kit (Pierce Biotechnology) according to the manufac-
turer’s protocol.
For SDS–PAGE, protein lysates (100 mg) were denatured
at 708Ci n4   sample buffer (Invitrogen) for 10 min, separ-
ated on 4–12% Tris-glycine acrylamide gels and electro-
transferred to polyvinylidene ﬂuoride (PVDF) membranes
(Millipore). All immunoblotting procedures were carried out
in 5% non-fat dry milk in 1  Tris-buffered saline (TBS).
The antibodies used are as follows: rabbit anti-AR (N-20;
sc-816, Santa Cruz Biotechnology; 1:1000), mouse
anti-cytochrome C (MSA06; Mitosciences; 1:1000), rabbit
anti-Bax (sc-493; Santa Cruz Biotechnology; 1:500), rabbit
anti-phospho Bad (9295S; Cell Signaling Technology;
1:500), rabbit anti-Bad (9292; Cell Signaling Technology;
1:500), rabbit anti-SOD2 (SOD-110; Stressgen; 1:500),
mouse anti-Hsp60 (SPA-829; Stressgen; 1:500), mouse anti-
OxPhos complex IV (A6403; Invitrogen; 2 mg/ml), mouse
anti-porin (A31855; Invitrogen; 0.5 mg/ml), mouse
anti-a-tubulin (T9026; Sigma; 1:1000) and mouse anti-
HDAC1 (89910; Pierce; 1:1000). Immunodetection was done
with horse radish peroxidase-conjugated goat anti-rabbit or
anti-mouse IgG (1:15,000; Jackson Immunoresearch), and
visualized with enhanced chemiluminescence reagent
(Perkin-Elmer) following the manufacturer’s instructions.
Re-probing of the blots was done after stripping the blots
with Re-blot Plus (Chemicon) according to manufacturer’s
protocol. Densitometric quantitation of the resultant bands
was done with Image J software (NIH, Bethesda) and
protein amounts were normalized to loading controls
(tubulin for total lysates and cytosolic fractions, porin for
mitochondria and HDAC1 for nuclear fractions). The values
were normalized to the mean of the vehicle-treated MN-1
cells, uninduced normal PC12 cells or normal (AR-21Q)
mice, which were each assigned as 1. Phosphorylated Bad
was normalized to total Bad levels. Cytochrome C release
was determined as the ratio of cytosolic to mitochondrial cyto-
chrome C.
Immuno-electron microscopy
MN-1 cells were plated on Permanox chambered slides
(Lab-Tek; Nunc) and exposed to vehicle control or the andro-
gen ligands for 24 h. Cells for immunogold labeling were ﬁxed
with ice cold 4% paraformaldehyde in PBS for 1 h at room
temperature followed by blocking and permeablization with
5% goat serum/0.1% saponin for 1 h. The cells were then incu-
bated with anti-AR antibodies (1:100; N20, Santa Cruz Bio-
technology) in 5% goat serum/0.1% saponin for 1.5 h at
room temperature. After three 10 min washes in 1% goat
serum/1X PBS and two 10 min washes in 2% dry milk, they
were incubated with Nanogold-conjugated secondary antibody
(1:250; Nanoprobes) for 1 h at room temperature. Following
four 10 min washes in 2% dry milk/1X PBS the cells were
ﬁxed in 2% glutaraldehyde/1X PBS for 30 min. The slides
were subjected to staining and silver enhancement as
described previously (79). After dehydration, silver enhance-
ment, embedding and sectioning, the samples were examined
with an electron microscope (1200EX; JEOL). Electron micro-
graphs of 12–15 cells were acquired and the mitochondria
quantiﬁed by two independent researchers blinded to the
source of the sample. The number of mitochondria per cell
and the number of AR positive mitochondria were quantiﬁed.
Immunogold particles appearing as electron dense dark spots
within and in the peripheral areas (within 30 nm) of the mito-
chondria were counted as AR associated with the organelle.
This distance was approximated based on the lengths of two
15 nm long IgG molecules separating the gold and the
antigen (80).
Cell death assays
We used a ﬂow cytometry-based cell death assay as previously
published (81). MN-1 and PC12 cells seeded at 2   10
5 and
3   10
5 cells /well in six well dishes were exposed to the
vehicle control or the androgen ligands (R1881 and DHT),
1 mM staurosporine, 500 ng/ml antimycin A, 200 nM each of
CsA, CoQ10 and idebenone. Except for staurosporine (4 h)
and antimycin (16 h) treatments, the rest of the treatments
were for 48 h. The cells were then trypsinized, gently pelleted
and re-suspended in 1 ml of 1X PBS. The suspensions were
then stained with 1 mg/ml propidium iodide (PI; Sigma)
immediately before ﬂow cytometry (Becton Dickinson
FACS Calibur). For each sample, 80 000 non-gated events
were acquired. PI ﬂuorescence was analyzed in the FL-3
channel in dot and density blot formats. The results were
expressed as a percentage of PI-positive dead cells divided
by the total number of cells.
Statistics
All experiments were conducted at least twice with each con-
dition in triplicate. Comparisons between any two groups of
data were done using the single-factorial analysis of variance
(ANOVA). A P-value of  0.05 was considered statistically
signiﬁcant. Numerical data were expressed as averages +
the standard error of mean (SEM).
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